Medico Intercontinental swings to ₹10.98 cr loss as subsidiaries bleed
The company reported a ₹5.01 cr profit in FY25, but consolidated losses now eclipse the parent entity's standalone earnings.
What's new
- Consolidated net profit of ₹5.01 cr in FY25 flipped to a ₹10.98 cr loss in FY26.
- Parent company standalone profit dropped to ₹2.18 cr from ₹2.57 cr.
- Consolidated revenue fell to ₹84.58 cr, down from ₹95.31 cr the prior year.
Why this matters
The gap between standalone and consolidated performance indicates the group is failing to contain subsidiary-level outflows. For a company with a market cap of only ₹23 cr, absorbing a loss nearly half that size in a single year leaves little room for error.
What we're watching
- Whether the new joint venture accounting policy masks or reveals further instability.
- If the parent company can absorb more subsidiary losses without a capital raise.
- Any management commentary on the specific subsidiaries driving the deficit.
The full read
Medico Intercontinental ended FY26 with a consolidated loss of ₹10.98 crore, a stark reversal from the previous year’s ₹5.01 crore profit.
Subsidiaries are bleeding the parent dry.
While the standalone business remained functional with a profit of ₹2.18 crore, it could not offset the heavy outflows occurring within the group’s broader operations. Quarterly performance confirms that the negative trajectory is accelerating; the company posted a consolidated loss of ₹2.33 crore for the final quarter, whereas it booked a profit of ₹1.17 crore during the same period last year. With consolidated revenue shrinking to ₹84.58 crore from ₹95.31 crore, the firm is grappling with both top-line decay and collapsing margins. Considering the company's total market valuation sits at a mere ₹23 crore, the magnitude of these losses suggests a precarious financial future for shareholders. The board’s recent decision to adopt a new accounting policy for joint ventures and reappoint its internal auditor does little to mask the core issue.